Halozyme Therapeutics (NASDAQ:HALO) and Vertex Pharmaceuticals (NASDAQ:VRTX) announced a global exclusive collaboration and license agreement on April 7, 2026, aimed at leveraging Halozyme’s proprietary Hypercon™ microparticle technology to transform the delivery of biologic therapies.
Under the terms of the agreement, Vertex will be granted access to the Hypercon platform for up to three undisclosed drug targets.
Halozyme will receive an upfront payment of $15 million, with the potential for additional future milestone payments tied to development, regulatory, and commercial achievements.
Furthermore, Halozyme is entitled to receive tiered royalties on any future net sales of products developed using the technology.
The partnership focuses on Hypercon’s "hyperconcentration" capability, a technology designed to enable the delivery of high-dose biologics in small-volume subcutaneous injections.
By reducing the physical volume of the medication, the collaboration aims to shift therapies from traditional hospital-based intravenous infusions to simplified, at-home subcutaneous dosing.